AEZS - エテルナ・ゼンタリス (AEterna Zentaris Inc.) エテルナ・ゼンタリス

 AEZSのチャート


 AEZSの企業情報

symbol AEZS
会社名 AEterna Zentaris Inc (エテルナ・ゼンタリス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エテルナ・ゼンタリス(AEterna Zentaris Inc.)は腫瘍と内分泌療法を専門にする医薬品開発企業。同社の製品パイプラインは創薬から市販製品までの開発のすべての段階における化合物を含む。腫瘍における優先順位は多発性骨髄腫に対するペリホシンを投与したフェーズ3プログラムと転移性大腸癌を含む多発性癌に対するフェーズ2プログラム、並びに進行性子宮内膜癌と進行性卵巣癌に対するAEZS-108を投与したフェーズ2プログラム、また他の癌適応症における潜在的な発展を含む。内分泌では同社のプログラムは成人成長ホルモン分泌不全症(AGHD)の診断のための成長ホルモン(GH) 刺激試験とするAEZS-130(SolorelTM)を投与したフェーズ3相試験の再活性化である。   エテルナ・ゼンタリスはカナダのバイオ医薬品メ―カ―。腫瘍及び内分泌疾患の治療法の開発、商業化に従事。パイプラインは、薬品の発見から開発、製品の販売までが含まれる。製品候補には、小児充実性腫瘍、子宮内膜がん、卵巣がん、前立腺がん、がん悪液質などの新治療薬がある。本社はカナダケベック州。   Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. It operates through biopharmaceutical segment. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Charleston, SC.
本社所在地 1405 du Parc-Technologique Blvd. Quebec City Quebec G1P 4P5 CAN
代表者氏名 Carolyn Egbert キャロリン・エグベルト
代表者役職名 Independent Chairman of the Board
電話番号 +1 843-900-3223
設立年月日 33117
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 56人
url www.aezsinc.com
nasdaq_url https://www.nasdaq.com/symbol/aezs
adr_tso
EBITDA EBITDA(百万ドル) 5.17900
終値(lastsale) 1.67
時価総額(marketcap) 27456069.2
時価総額 時価総額(百万ドル) 28.28272
売上高 売上高(百万ドル) 25.24500
企業価値(EV) 企業価値(EV)(百万ドル) 8.33672
当期純利益 当期純利益(百万ドル) 1.70700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AEterna Zentaris Inc. (USA) revenues increased from $504K to $24.8M. Net income totaled $11.8M vs. loss of $6.7M. Revenues reflect Licensing revenue increase from $220K to $24.7M. Net Income reflects Research and development costs net of r decrease of 70% to $1.8M (expense) Selling expenses decrease of 29% to $2.1M (expense).

 AEZSのテクニカル分析


 AEZSのニュース

   The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data  2019/12/18 12:23:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Medtronic PLC (NYSE: MDT )(announced acquisition of Klue, a software company focused on behavior tracking) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nantkwest Inc (NASDAQ: NK ) Novo Nordisk A/S (NYSE: NVO ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) NuVasive, Inc. (NASDAQ: NUVA ) Ovid Therapeutics Inc (NASDAQ: OVID ) Prevail Therapeutics Inc (NASDAQ: PRVL )( announced Orphan Drug Designation for its dementia asset) Principia Biopharma Inc (NASDAQ: PRNB ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) ResMed Inc. (NYSE: RMD ) Soligenix, Inc.
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win  2019/12/12 12:38:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
   The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data  2019/12/18 12:23:31 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Medtronic PLC (NYSE: MDT )(announced acquisition of Klue, a software company focused on behavior tracking) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nantkwest Inc (NASDAQ: NK ) Novo Nordisk A/S (NYSE: NVO ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) NuVasive, Inc. (NASDAQ: NUVA ) Ovid Therapeutics Inc (NASDAQ: OVID ) Prevail Therapeutics Inc (NASDAQ: PRVL )( announced Orphan Drug Designation for its dementia asset) Principia Biopharma Inc (NASDAQ: PRNB ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) ResMed Inc. (NYSE: RMD ) Soligenix, Inc.
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win  2019/12/12 12:38:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.
   The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares  2019/12/10 12:56:02 Benzinga
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
   Aeterna Zentaris misses by $0.34, misses on revenue  2019-05-07
Aeterna Zentaris (NASDAQ: AEZS ): Q1 GAAP EPS of -$0.30 misses by $0.34 . Revenue of $0.04M (-99.8% Y/Y) misses by $4.16M . Press Release More news on: Aeterna Zentaris Inc., Earnings news and commentary, Healthcare stocks news, ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エテルナ・ゼンタリス AEZS AEterna Zentaris Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)